Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27
August 13, 2020 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe
August 12, 2020 07:05 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
August 04, 2020 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
July 07, 2020 22:11 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, July 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
July 06, 2020 12:58 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan
July 06, 2020 09:24 ET
|
Ascendis Pharma
– Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age – – Company on track to submit European...
Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
June 26, 2020 08:29 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, June 26, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
June 22, 2020 08:30 ET
|
Ascendis Pharma
- In vitro data demonstrated selective binding and activation of IL-2 β/γ receptor, associated with reduced IL-2 α receptor binding - - Selective expansion and activation of cells in vivo consistent...
Ascendis Pharma A/S Announces Participation in ENDO Online 2020
June 08, 2020 08:15 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, June 08, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical...
Ascendis Pharma A/S Reports First Quarter 2020 Financial Results
May 19, 2020 16:01 ET
|
Ascendis Pharma
– On track for filing U.S. Biologics License Application for TransCon hGH in second quarter, and advancing Marketing Authorisation Application in Europe to third quarter – – Expanded commercial...